Azenta Life Sciences has officially opened its state-of-the-art biorepository facility in the Greater Boston area, designed to serve the unique storage and management needs of the biotech and life sciences industries. Located strategically to support Cambridge and Boston’s vibrant community of...
Rebecca Ihilchik, MA Stacey Johnson, MSc CCRM The discourse around artificial intelligence (AI) is seemingly everywhere nowadays. Increasingly influential in our everyday lives, AI has transformed multiple industries and is only gaining speed. This may lead professionals in the cell and...
STEMCELL Technologies Human hematopoietic cells are generated in waves during development. The first wave produces mainly primitive blood cells that serve the early needs of the growing embryo. Later waves give rise to multipotent hematopoietic stem and progenitor cells (HSPCs), which show...
New Facilities in Houston, Tx and Villers-le-Bouillet, Belgium Strengthen Cryoport Systems’ Global Leadership in Temperature-Controlled Supply Chain Services (Houston, Tx, USA and Villers-le-Bouillet, BELGIUM) Cell therapies are revolutionizing medicine, providing new hope for conditions...
By Olga Bukatova, Associate Director of Business Development, CGT, Azenta Life Sciences With a projected rate of 10-20 product approvals per year, the global cell and gene therapy (CGT) industry is rapidly evo lvi ng. The clinical pipeline delivers a promise to the patient population...
Article Provided by Miltenyi Biotec Despite a turbulent market environment, the cell and gene therapy (CGT) field continues to advance, with several groundbreaking therapies slated to receive FDA approval this year alone. The momentum is undeniable. However, the path from clinical development...
Erica Waller Senior Product Manager Cryo Automation and Stores Azenta Life Sciences Burlington, MA, USA Cryopreservation, the process of preserving cells, tissues, and organs at extremely low temperatures, stands out as a pivotal technique in modern medicine. As we push the boundaries of...
Sponsored Article provided by Akron Biotech Robert Margolin Vice President, Commercial Akron BioProducts Ezequiel Zylberberg Vice President, Corporate Development Akron BioProducts Allen Parsons Associate, Regulatory Affairs Akron Bio Mahajoub Bello...
Pittsburgh, Pa., August 23, 2024 — Cook MyoSite announced that the first participant was treated in the DigniFI Study, a two-stage, randomized, controlled Phase III trial comparing the safety and efficacy of iltamiocel with placebo in the treatment of female participants with chronic fecal...
by Fajar Dumadi, BSc Regulatory Program Specialist ISCT Head Office This draft guidance provides recommendations for developing a science- and risk-based strategy to help assure the potency of a human cellular therapy or gene therapy (CGT) product. This draft guidance document, when finalized...